Kendle Advances Early Stage Drug Development with ElMindA's Innovative Brain Network Activation Technology

Kendle and ElMindA partner in the introduction of a unique technology providing objective, sensitive, neural network profiling of brain activity

CINCINNATI, June 15, 2010 - Kendle (Nasdaq: KNDL), a leading, global full-service clinical research
organization, today announced it now offers Brain Network Activation (BNA)
imaging providing a non-invasive platform for mapping, monitoring and
understanding brain electro-physiological network activity in response to
cognitive or physiological stimuli. The BNA imaging technology was developed
by ElMindA, a medical technology development company based in Herzliya,
Israel. Exclusively licensed to Kendle's early stage development efforts,
this innovative solution reveals electrophysiological neural networks by
using an innovative set of signal processing and pattern recognition
techniques that combine the high temporal resolution of EEG with the spatial
resolution of fMRI. The result is a three-dimensional image of neuronal
connectivity and synchronization providing sensitive, specific and
reproducible data on drug effects essential for early stage development.

"This technology represents a sizeable step forward in our ability to
evaluate the effectiveness of CNS drugs early in their development by
directly and objectively observing the brain's response to them," said Ed
Sellers, MD, PhD, FRCPC, FACP, Vice President, Early Stage, Kendle. "BNA is
faster, less expensive and more accessible than other brain imaging solutions
currently on the market because all scanning can be done in house. Ultimately
this translates into powerful, abundant data and expedited go/no-go decisions
for our customers, saving them time and money."

The BNA technology utilizes standard 64 electrode EEG and can be applied
in any clinic by an EEG-trained technician rather than requiring scanning
time in MRI machines. There are no limits to the number of scans or images
that can be taken over a set amount time as EEG is completely non-invasive,
allowing for assessments at multiple time points and multiple doses to
determine the effects of novel drugs on brain function.

"ElMindA's mission in developing BNA imaging was to revolutionize the
diagnosis and treatment of brain-related pathologies by showing, for the
first time, the dynamic connectivity and synchronization of
electrophysiological networks within the brain," said Professor Amir Geva,
Founder and Chief Technology Officer of ElMindA. "We are enabling researchers
and physicians to truly observe the direct electrophysiology of the brain
reacting to treatment in order to improve a wide range of therapies. Kendle
was the ideal partner to bring this exclusive technology to market because of
their extensive early stage CNS experience."

The BNA technology is expected to accelerate research in such key areas
as Alzheimer's disease, mild cognitive impairment, schizophrenia, pain, ADHD,
depression, anxiety, sleep disorders and narcolepsy and can be adapted to any
study of drugs expected to act on the central nervous system. BNA is ideal
for SAD/MAD discovery, proof-of-concept and proof-of-mechanism studies,
patient bridging and identifying select responder populations. The
highly-sensitive imaging also can capture dose-dependent changes in the
brain, allowing for evaluation of drug-drug interactions and improved
participant selection criteria.

"The technology has been targeted to early stage CNS drugs very early in
their development, allowing us to literally see if and how a drug is working
by evaluating cognition or subjective measures of response coupled with
network activation patterns," noted Dr. Sellers.

BNA technology is available immediately to Kendle customers through the
Company's early stage units in Toronto, Canada and Utrecht, The Netherlands.
Kendle is a worldwide leader in early stage clinical development, providing
high-end scientific exploratory/translational medicine expertise from
first-in-human studies through Phase IIa/proof-of-concept. The Company offers
unrivalled expertise in the conduct of studies involving the measurement of
pharmacodynamic parameters, particularly in drugs acting on the Central
Nervous System. Kendle's early stage core competencies include neurocognitive
assessment, abuse liability assessment and pharmacogenomics. The Company's
offerings also include bioequivalence and bioavailability services for
customers in the generics industry.

About ElMindA

ElMindA Ltd. develops and markets a non-invasive, diagnosis and treatment
management platform that addresses a critical unmet need in neurological and
psychiatric disorders to dramatically enhance treatment efficacy and
patients' quality of life while reducing costs. ElMindA's mission is to
revolutionize the treatment of brain-related pathologies by revealing, for
the first time ever, the dynamic electrophysiological neural network
connectivity and synchronization of the brain, paving the way to affecting
brain plasticity and empowering the dramatic improvement of brain disorder
treatment at any neurological and psychiatric point of care. ElMindA's
platform can be utilized for a wide range of neurological and psychiatric
applications and is currently available for clinical development. ElMindA is
located at 16 Haminhara St., Beit Bachar Herzliya 46586, Israel. For more
information visit www.elminda.com.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical
research organization providing the full range of early- to late-stage
clinical development services for the world's biopharmaceutical industry. Our
focus is on innovative solutions that reduce cycle times for our customers
and accelerate the delivery of life-enhancing drugs to market for the benefit
of patients worldwide. As one of the world's largest global providers of
Phase I-IV services, we offer experience spanning more than 100 countries,
along with industry-leading patient access and retention capabilities and
broad therapeutic expertise, to meet our customers' clinical development
challenges.

Additional information and investor kits are available upon request from
Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the
Company's Web site at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be
deemed to be forward-looking statements under federal securities laws and the
provisions of the Private Securities Litigation Reform Act of 1995 and Kendle
intends that such forward-looking statements be subject to the safe-harbor
created thereby. All such forward-looking statements, including those
regarding the benefits of Kendle's use of ElMindA Brain Network Activation
technology are based largely on management's expectations and are subject to
and qualified by risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements. These
risks and uncertainties include those risks as detailed from time to time in
Kendle's Annual Report on Form 10-K as well as periodic reports filed with
the SEC. All information in this press release is current as of June 15,
2010. The Company undertakes no duty to update any forward-looking statement
to conform the statement to actual results or changes in the Company's
expectations.

Michael Lawson, Investors, +1-513-763-1992; or Lori Dorer, Media, +1-513-345-1685